Abstract
Cellular immunotherapies such as CAR-T cell therapy and TCR-T cell therapy are relatively new, highly promising approaches for the treatment of cancer. In CAR-T cell therapy, a patient's T cells are engineered to express chimeric antigen receptors targeting tumor-associated cell surface antigens. In TCR-T cell therapy, the patient's T cells are engineered to express receptors targeting intracellular antigens. This report will summarize presentations from the recent CAR-TCR summit in Boston on September 13-16, 2016. These presentations were given by leaders in the field and many were divided into three streams: Discovery and Genetic T Cell Engineering; Translation and Clinical Development; and Manufacturing, Supply Chain and Commercialization. The report summarizes major pharmaceutical companies developing these novel therapies and provides challenges and perspectives for future therapeutic developments.
Keywords: Chimeric antigen receptor, immunotherapy, cytokine, cancer, tumor antigen, T-cell enginering.
Anti-Cancer Agents in Medicinal Chemistry
Title:Major Highlights of the CAR-TCR Summit, Boston, 2016
Volume: 17 Issue: 10
Author(s): Vita Golubovskaya*, Robert Berahovich, Shirley Xu, Hizkia Harto and Lijun Wu*
Affiliation:
- Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806,United States
- Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806,United States
Keywords: Chimeric antigen receptor, immunotherapy, cytokine, cancer, tumor antigen, T-cell enginering.
Abstract: Cellular immunotherapies such as CAR-T cell therapy and TCR-T cell therapy are relatively new, highly promising approaches for the treatment of cancer. In CAR-T cell therapy, a patient's T cells are engineered to express chimeric antigen receptors targeting tumor-associated cell surface antigens. In TCR-T cell therapy, the patient's T cells are engineered to express receptors targeting intracellular antigens. This report will summarize presentations from the recent CAR-TCR summit in Boston on September 13-16, 2016. These presentations were given by leaders in the field and many were divided into three streams: Discovery and Genetic T Cell Engineering; Translation and Clinical Development; and Manufacturing, Supply Chain and Commercialization. The report summarizes major pharmaceutical companies developing these novel therapies and provides challenges and perspectives for future therapeutic developments.
Export Options
About this article
Cite this article as:
Golubovskaya Vita*, Berahovich Robert, Xu Shirley, Harto Hizkia and Wu Lijun*, Major Highlights of the CAR-TCR Summit, Boston, 2016, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (10) . https://dx.doi.org/10.2174/1871520617666170110151900
DOI https://dx.doi.org/10.2174/1871520617666170110151900 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Designing Novel Molecules for Anti-Cancer Enzyme Modulation: A Mechanistic and Therapeutic Perspective
The deficiencies or hyper functions of enzymes cause a number of diseases. Enzyme inhibition is an important area of pharmaceutical research since studies in this field have already led to the discovery of wide variety of drugs useful in a number of diseases. Specific inhibitors interact with enzymes and block ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Heterocyclic Systems: Bridging Chemistry and Biology in Cancer Therapy
The thematic issue, "Heterocyclic Systems: Bridging Chemistry and Biology in Cancer Therapy," explores the critical role of heterocyclic compounds in advancing the frontiers of cancer treatment. Heterocycles serve as fundamental building blocks in medicinal chemistry due to their structural diversity and ability to interact with biological targets. This issue aims ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetics of Virus-Induced Tumors: Perspectives for Therapeutic Targeting
Current Pharmaceutical Design Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene
Current Cancer Therapy Reviews Therapeutic Potential of HDAC Inhibitors in the Treatment of Cardiac Diseases: A Short Review
Current Drug Targets Biology of Cox-2: An Application in Cancer Therapeutics
Current Drug Targets In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment
Current Medicinal Chemistry Mini-Review: Nucleus-Targeted Ribonucleases As Antitumor Drugs
Current Medicinal Chemistry Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design Physiological and Molecular Role of Ranpirnase on Cancer Treatment
Current Cancer Therapy Reviews Platelet-Rich Plasma Induces Mixed Osteogenic/Osteoclastogenic Phenotype in Osteosarcoma SaOS-2 Cells: Role of TGF-Beta
Current Pharmaceutical Biotechnology JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells
Current Cancer Drug Targets A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Current Drug Targets Oncolytic Viruses: The Best is Yet to Come
Current Cancer Drug Targets EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research CSPG4 in Cancer: Multiple Roles
Current Molecular Medicine The Drug Targeting and Delivery Approach Applied to Pt-Antitumour Complexes. A Coordination Point of View
Current Medicinal Chemistry Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry γ-Tocotrienol Induces Apoptosis in Human T Cell Lymphoma through Activation of Both Intrinsic and Extrinsic Pathways
Current Pharmaceutical Design